Please login to the form below

Not currently logged in
Email:
Password:

Amgen's Glenn Begley joins Oxford BioTherapeutics as a clinical advisor

Begley was formerly president and global head of haematology and oncology research at US biotech Amgen

Glenn Begley - Oxford BioTherapeuticsGlenn Begley, former president and global head of haematology and oncology research at US biotech Amgen, has been appointed senior clinical advisor and non-executive director at Oxford BioTherapeutics.

He spent over ten years leading Amgen's cancer strategy, overseeing the progression of 24 molecules into clinical development.

In his new role he is expected to help shape and deliver Oxford BioTherapeutics's clinical and corporate strategy to bring its pipeline of oncology antibody-based drugs into clinical development.

Dr Christian Rohlff, CEO of Oxford BioTherapeutics, said: “[Glenn's] wealth of relevant clinical and commercial expertise in the oncology and antibody field will be instrumental in helping Oxford BioTherapeutics to transition into a successful clinical development organisation.”

The UK biotech's research focus is on antibody-based cancer medicines using novel drug targets identified through the firm's Oxford Genome Anatomy Project (OGAP) – a database that contains data on over 7,500 cancer membrane proteins. Companies signed up to work with Oxford BioTherapeutics using this technology include Bristol-Myers Squibb, GlaxoSmithKline and Sanofi.

Dr Begley said: “I am excited by this unique opportunity to join a high-calibre team at a rapidly advancing biotech company with an impressive pipeline of preclinical cancer programmes and network of collaborators / licensing partners.”

13th January 2012

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Fishawack Group of Companies

The Fishawack Group of Companies is one of the largest independent medical communications and medical marketing specialists, with teams in...

Latest intelligence

Has the pandemic opened up a future of accelerated diagnosis and better care for rare disease patients?
The challenge with rare disease is in the name – it's rare, so awareness is limited and diagnosis hindered. Could a more virtual existence change this? A Medical Affairs viewpoint...
The other side of … blood cancer
To stay motivated for the fight, some patients need to feel like active players in the treatment journey, not passengers to every decision....
COVID clinical trial
COVID-19 – a catalyst for technology adoption in clinical trials
As the COVID-19 crisis disrupts clinical trials around the globe, it is also proving to be a catalyst that may transform its approach to trials for good...

Infographics